American biotechnology company Moderna released a press release on Monday announcing that their COVID-19 vaccine has an efficacy rate of 94.5 percent. An independent review by an NIH-appointed Data Safety Monitoring Board (DSMB) confirmed the results.
This news comes after a large test undertaking called the "COVE study" which enrolled more than 30,000 participants in the U.S.
Moderna intends to submit for an Emergency Use Authorization (EUA) with the US Food and Drug Administration (FDA) in the coming weeks. Moderna also plans to apply for authorization from global regulatory agencies.
This announcement comes just a week after US pharmaceutical company Pfizer announced their COVID-19 vaccine is 90 percent effective. Both of the vaccines require people to get two shots, several weeks apart.
On top of their promising announcement, Moderna also says the vaccine will be able to be stored for 30 days in warmer temperatures than that of many other vaccines in development. This allows longer shelf life and easier transportation of the vaccine.
Moderna says studies are ongoing and more information is incoming. Leading up to the final analysis, Moderna expects the point estimate for vaccine efficacy may change. The company plans to submit data from the full Phase 3 COVE study to a peer-reviewed publication.
Powered by StructureCMS™ Comments
Join and support independent free thinkers!
We’re independent and can’t be cancelled. The establishment media is increasingly dedicated to divisive cancel culture, corporate wokeism, and political correctness, all while covering up corruption from the corridors of power. The need for fact-based journalism and thoughtful analysis has never been greater. When you support The Post Millennial, you support freedom of the press at a time when it's under direct attack. Join the ranks of independent, free thinkers by supporting us today for as little as $1.
Remind me next month
To find out what personal data we collect and how we use it, please visit our Privacy Policy
Comments